OTCMKTS:GBLX GB Sciences (GBLX) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free GBLX Stock Alerts $0.0067 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0050▼$0.006850-Day Range$0.0052▼$0.007852-Week Range$0.01▼$0.02Volume81,311 shsAverage Volume121,798 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get GB Sciences alerts: Email Address Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About GB Sciences Stock (OTCMKTS:GBLX)GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.Read More GBLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GBLX Stock News HeadlinesMarch 12, 2024 | bbc.comGB News posts £42m loss but grows online audienceDecember 14, 2023 | finance.yahoo.comGb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)April 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.November 2, 2023 | dailymail.co.ukTeam GB News: Medals and Schedule at Winter OlympicsOctober 8, 2023 | mirror.co.ukDan Wootton's replacement on GB News revealed as he's suspended over Laurence Fox rantOctober 6, 2023 | mirror.co.ukGB News boss explains why Dan Wootton is still on air amid allegations against presenterOctober 3, 2023 | mirror.co.ukGB News suspends third presenter for supporting Dan Wootton in Laurence Fox rowOctober 2, 2023 | dailymail.co.ukGB News - Updates on the British television news channelApril 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.July 11, 2023 | finance.yahoo.comGb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of LethbridgeJune 20, 2023 | reuters.comINSIGHT-Lab crunch: British science has nowhere to goMay 27, 2023 | finance.yahoo.comGBLX - GB Sciences, Inc.March 20, 2023 | finance.yahoo.comGB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in ChinaMarch 7, 2023 | finance.yahoo.comSuccessful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery PlatformFebruary 18, 2023 | benzinga.comGB Sciences Stock (OTC:GBLX), Quotes and News SummaryDecember 26, 2022 | benzinga.comGb Sciences Identifies Novel Cannabis-Inspired Mixtures That Could Treat Viral InfectionsDecember 12, 2022 | finance.yahoo.comGb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based FormulationsNovember 1, 2022 | msn.comCannabis Terpenes Reduce Inflammation, Says Gb Sciences StudyNovember 1, 2022 | finance.yahoo.comGb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis IngredientsOctober 27, 2022 | finance.yahoo.comTODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic SummitOctober 24, 2022 | finance.yahoo.comGb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyOctober 13, 2022 | finance.yahoo.comTODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 ConferenceOctober 10, 2022 | msn.comNew Study Shows Promising Results In Treatment Of Parkinson's Disease With CannabinoidsOctober 10, 2022 | finance.yahoo.comGb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's DiseaseSeptember 6, 2022 | finance.yahoo.comTODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal ArticleAugust 9, 2022 | ca.finance.yahoo.comGB Sciences, Inc. (GBLX)July 20, 2022 | stockhouse.comGb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform-PhAROS(TM)See More Headlines Receive GBLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GB Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2016Today4/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryCannabis Current SymbolOTCMKTS:GBLX CUSIPN/A CIK1165320 Webgbsciences.com Phone(866) 721-0297FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. John Claybron Poss (Age 76)CEO, Interim CFO & Chairman Comp: $60kDr. Andrea Small-Howard M.B.A. (Age 55)MBA, Ph.D., Chairman of Scientific Advisory Board, Chief Science Officer, President & Director Comp: $138kMr. Gary R. Henrie Esq. (Age 70)Securities Counsel & Company Secretary Key CompetitorsCNBX PharmaceuticalsOTCMKTS:CNBX180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All Competitors GBLX Stock Analysis - Frequently Asked Questions How have GBLX shares performed in 2024? GB Sciences' stock was trading at $0.0064 at the beginning of 2024. Since then, GBLX stock has increased by 4.8% and is now trading at $0.0067. View the best growth stocks for 2024 here. Are investors shorting GB Sciences? GB Sciences saw a decrease in short interest in April. As of April 15th, there was short interest totaling 900 shares, a decrease of 10.0% from the March 31st total of 1,000 shares. Based on an average daily volume of 218,100 shares, the short-interest ratio is currently 0.0 days. View GB Sciences' Short Interest. How were GB Sciences' earnings last quarter? GB Sciences, Inc. (OTCMKTS:GBLX) announced its quarterly earnings data on Monday, November, 14th. The company reported ($0.04) earnings per share for the quarter. What other stocks do shareholders of GB Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other GB Sciences investors own include KushCo (KSHB), Medical Marijuana (MJNA), CNBX Pharmaceuticals (CNBX), MassRoots (MSRT), Surna (SRNA), Gran Tierra Energy (GTE), GreenGro Technologies (GRNH), MariMed (MRMD), Pennsylvania Real Estate Investment Trust (PEI) and Diamond Wellness (POTN). How do I buy shares of GB Sciences? Shares of GBLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GBLX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GB Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
